EMEPRONIUM BROMIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C20H28N.Br
Molecular Weight	362.347
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Br-].CC[N+](C)(C)C(C)CC(C1=CC=CC=C1)C2=CC=CC=C2

InChI

InChIKey=UVKFSMBPRQBNCH-UHFFFAOYSA-M

InChI=1S/C20H28N.BrH/c1-5-21(3,4)17(2)16-20(18-12-8-6-9-13-18)19-14-10-7-11-15-19;/h6-15,17,20H,5,16H2,1-4H3;1H/q+1;/p-1

HIDE SMILES / InChI

Molecular Formula	BrH
Molecular Weight	80.912
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C20H28N
Molecular Weight	282.443
Charge	1
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4024956 | https://dtb.bmj.com/content/6/23/91 | https://www.ncbi.nlm.nih.gov/pubmed/364631

Emepronium bromide (Cetiprina) is a quarternary ammonium compound with anticholinergic effects. It is mainly used in the treatment of urinary frequency, urge and urge incontinence and is usually administered orally and occasionally intramuscularly. Emepronium bromide was introduced into Britain, after having been used in Sweden for a number of years. The drug was advocated especially for elderly patients suffering from nocturia and urgency with incontinence, when these were due to causes other than obstruction. It was also advocated for enuresis and hypertonic bladder states following surgery or radiotherapy.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Muscarinic acetylcholine receptor 160 Target ID: CHEMBL2094109 Sources: http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&s1=%2720090247628%27.PGNR.&OS=DN/20090247628&RS=DN/20090247628	Modulator 828

PubMed

Title	Date	PubMed
Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.	2002	12137711
Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.	2006 Oct 18	17054185
Medical management of overactive bladder.	2010 Apr	20877608
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443
[A drug seeks its disease].	2010 Jun 2-8	20645604

Patents

Sample Use Guides

In Vivo Use Guide

Intravenous doses of 1, 5, 10 and 15 mg of emepronium bromide were given to three healthy volunteers.

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:03:47 GMT 2023` Edited by `admin` on `Fri Dec 15 18:03:47 GMT 2023`
Record UNII	WZM699L2TL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EMEPRONIUM BROMIDE

Official Name

English

BENZENEPROPANAMINIUM, N-ETHYL-N,N,.ALPHA.-TRIMETHYL-.GAMMA.-PHENYL-, BROMIDE (1:1)

Systematic Name

English

Emepronium bromide [WHO-DD]

Common Name

English

CETIPRIN

Brand Name

English

EMEPRONIUM BROMIDE [MART.]

Common Name

English

RESTENACHT

Brand Name

English

AMMONIUM, ETHYLDIMETHYL(1-METHYL-3,3-DIPHENYLPROPYL)-, BROMIDE

Systematic Name

English

URO-RIPIRIN

Brand Name

English

ETHYLDIMETHYL(1-METHYL-3,3-DIPHENYLPROPYL)AMMONIUM BROMIDE

Systematic Name

English

HEXANIUM

Systematic Name

English

EMEPRONIUM BROMIDE [MI]

Common Name

English

BENZENEPROPANAMINIUM, N-ETHYL-N,N,.ALPHA.-TRIMETHYL-.GAMMA.-PHENYL-, BROMIDE

Systematic Name

English

emepronium bromide [INN]

Common Name

English

RIPIRIN

Brand Name

English

Code System Code Type Description

EPA CompTox

DTXSID50875265